Biogen Shares Drop After Updated Data on Alzheimer's Drug Diranersen
Biogen shares fell following the release of additional mid-stage trial data for diranersen, an experimental Alzheimer’s drug developed with Ionis Pharmaceuticals. The update comes after initial topline results were released in May.
Topics: Alzheimer's biotech clinical trials